XOMA (NASDAQ:XOMA) Lowered to “Sell” Rating by StockNews.com

StockNews.com downgraded shares of XOMA (NASDAQ:XOMA) from a hold rating to a sell rating in a report released on Friday.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $123.00 price objective on shares of XOMA in a report on Friday, December 13th.

XOMA Stock Down 3.6 %

Shares of NASDAQ:XOMA opened at $26.30 on Friday. XOMA has a fifty-two week low of $18.24 and a fifty-two week high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm’s 50-day simple moving average is $29.82 and its 200-day simple moving average is $27.80. The company has a market cap of $309.89 million, a price-to-earnings ratio of -7.56 and a beta of 0.88.

Insider Transactions at XOMA

In related news, CEO Owen Hughes sold 21,881 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares in the company, valued at $1,047,621.05. This represents a 38.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

A number of institutional investors have recently bought and sold shares of XOMA. BNP Paribas Financial Markets increased its position in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares in the last quarter. Rhumbline Advisers increased its holdings in XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares in the last quarter. Barclays PLC raised its position in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of XOMA in the third quarter valued at about $516,000. Finally, Bank of New York Mellon Corp grew its position in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.